Literature DB >> 18322802

Cushing's syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma.

R A Alwani1, S J C M M Neggers, M van der Klift, M G A Baggen, G J L H van Leenders, M O van Aken, A J van der Lely, W W de Herder, R A Feelders.   

Abstract

Ectopic adrenocorticotropin (ACTH) secretion accounts for less than 10% of all causes of endogenous Cushing's syndrome (CS) and is usually associated with neuroendocrine tumors and small cell carcinoma of the lung. We report the case of a 62-year-old man with CS due to ectopic ACTH production by small cell carcinoma of the prostate. He presented with severe hypercortisolism and associated symptoms. Plasma neuron specific enolase (NSE) was grossly elevated. Despite performing a laparoscopic bilateral adrenalectomy, the patient died as a result of sepsis with multi-organ failure. Post-mortem immunohistochemical staining of prostate tumor tissue showed ACTH expression. ACTH staining was also performed in four additional patients with small cell carcinoma of the urinary tract without CS. None of these additional cases showed a positive staining for ACTH. Although a rare cause of ectopic ACTH production, neuroendocrine prostate carcinoma should be considered in male patients with Cushing's syndrome, in particular in those with an occult source of ACTH overproduction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18322802     DOI: 10.1007/s11102-008-0100-z

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  28 in total

1.  Mechanisms of androgen-refractory prostate cancer.

Authors:  Jose D Debes; Donald J Tindall
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

2.  Cabergoline plus lanreotide for ectopic Cushing's syndrome.

Authors:  Rosario Pivonello; Diego Ferone; Steven W J Lamberts; Annamaria Colao
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

Review 3.  The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.

Authors:  A Mosca; A Berruti; L Russo; M Torta; L Dogliotti
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

4.  Ectopic ACTH syndrome: our experience with 25 cases.

Authors:  Luiz Roberto Salgado; Maria Candida B Villares Fragoso; Mirta Knoepfelmacher; Marcio Carlos Machado; Sorahia Domenice; Maria Adelaide Albergaria Pereira; Berenice Bilharinho de Mendonça
Journal:  Eur J Endocrinol       Date:  2006-11       Impact factor: 6.664

Review 5.  Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities.

Authors:  Nadezda Vashchenko; Per-Anders Abrahamsson
Journal:  Eur Urol       Date:  2005-02       Impact factor: 20.096

6.  Carcinoma of the prostate with Cushing's syndrome. A case report with histochemical and chemical demonstration of immunoreactive corticotropin-releasing hormone in plasma and tumoral tissue.

Authors:  A Fjellestad-Paulsen; P A Abrahamsson; A Bjartell; M Grino; L Grimelius; H Hedeland; S Falkmer
Journal:  Acta Endocrinol (Copenh)       Date:  1988-12

7.  Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.

Authors:  Thomas Fixemer; Klaus Remberger; Helmut Bonkhoff
Journal:  Prostate       Date:  2002-10-01       Impact factor: 4.104

8.  Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications.

Authors:  L Delisle; M J Boyer; D Warr; D Killinger; D Payne; J L Yeoh; R Feld
Journal:  Arch Intern Med       Date:  1993-03-22

9.  ACTH precursors characterize the ectopic ACTH syndrome.

Authors:  P M Stewart; S Gibson; S R Crosby; R Penn; R Holder; D Ferry; N Thatcher; P Phillips; D R London; A White
Journal:  Clin Endocrinol (Oxf)       Date:  1994-02       Impact factor: 3.478

10.  Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine?

Authors:  G Francia; M V Davì; E Montresor; C Colato; M Ferdeghini; V Lo Cascio
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 5.467

View more
  7 in total

1.  Diagnosis of prostatic neuroendocrine carcinoma: Two cases report and literature review.

Authors:  Hai-Qing He; Shu-Feng Fan; Qiong Xu; Zhen-Jing Chen; Zheng Li
Journal:  World J Radiol       Date:  2015-05-28

Review 2.  Paraneoplastic syndromes in prostate cancer.

Authors:  Matthew K Hong; Jennifer Kong; Benjamin Namdarian; Anthony Longano; Jeremy Grummet; Christopher M Hovens; Anthony J Costello; Niall M Corcoran
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

Review 3.  Severe Cushing's syndrome due to small cell prostate carcinoma: a case and review of literature.

Authors:  M S Elston; V B Crawford; M Swarbrick; M S Dray; M Head; J V Conaglen
Journal:  Endocr Connect       Date:  2017-06-05       Impact factor: 3.335

4.  Comparison of diagnostic efficacy of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT in ectopic adrenocorticotropic hormone syndrome.

Authors:  Bing Zhang; Qiao He; Yali Long; Yuying Zhang; Xiaoyan Wang; Zhifeng Chen; Jianbo Liu; Xiangsong Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-23       Impact factor: 6.055

5.  ECTOPIC ADRENOCORTICOTROPIC HORMONE SYNDROME DUE TO METASTATIC PROSTATE CANCER WITH NEUROENDOCRINE DIFFERENTIATION.

Authors:  Malini Soundarrajan; Henry Zelada; Jean Victoria Fischer; Peter Kopp
Journal:  AACE Clin Case Rep       Date:  2019-04-25

6.  Dual Paraneoplastic Endocrine Syndromes Heralding Onset of Extrapulmonary Small Cell Carcinoma: A Case Report and Narrative Review.

Authors:  Jill B Feffer; Natalia M Branis; Jeanine B Albu
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-18       Impact factor: 5.555

7.  Multiple hormone secretion may indicate worse prognosis in patients with ectopic Cushing's syndrome.

Authors:  Ieva Lase; Ieva Strele; Malin Grönberg; Gordana Kozlovacki; Staffan Welin; Eva Tiensuu Janson
Journal:  Hormones (Athens)       Date:  2020-01-16       Impact factor: 2.885

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.